Free Trial
→ Your free stock pick for today (From Behind the Markets) (Ad)tc pixel
NASDAQ:CING

Cingulate Q3 2026 Earnings Date & Estimates

Cingulate logo
$4.98 -0.21 (-4.05%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$5.12 +0.14 (+2.71%)
As of 10/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cingulate is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Cingulate in Q3 2026

Cingulate is expected to post earnings of -$0.48 per share on revenue of $540 thousand. In the same quarter a year earlier Cingulate reported -$1.35 per share. Cingulate last reported on August 13, 2026, posting -$0.45 per share and beating the -$0.63 consensus estimate. Cingulate has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.48
Expected Revenue
$540 thousand
Prior-Year EPS
-$1.35

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.45 (Beat by +$0.18)
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Cingulate Q3 2026 Earnings FAQ

Cingulate (NASDAQ:CING) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Cingulate's Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Cingulate to post earnings of -$0.48 per share for Q3 2026.

The consensus revenue estimate for Cingulate is $540 thousand for Q3 2026.

Cingulate Earnings Headlines

A poorly understood brain region tracks the gap between expectations and reality
October 18, 2026  |  msn.comhttps://www.msn.com/en-us/science/biology/a-poorly-understood-brain-region-tracks-the-gap-between-expectations-and-reality/ar-AA2euPza
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
September 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/17/3363935/0/en/shane-schaffer-cingulate-chairman-ceo-to-present-smart-launch-approach-at-indegene-digital-summit-rethinking-commercialization-for-emerging-pharma.html
The 401k Email 70 Million Investors Might Delete
An email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will delete it without a second look. Larry Benedict says that would be a mistake. He calls this the decade's biggest opportunity and is naming the one ticker to watch before it arrives. Watch his free breakdown now.tc pixel
November 1 at 1:00 AM  |  Brownstone Research (Ad)
Psychedelic drug calms hyperactive brain cells linked to chronic pain
August 16, 2026  |  msn.comhttps://www.msn.com/en-us/health/general/psychedelic-drug-calms-hyperactive-brain-cells-linked-to-chronic-pain/ar-AA2aeGPA
Cingulate Reports $5.9 Million Second-Quarter Loss, $28.4 Million Cash
August 13, 2026  |  quiverquant.comQ
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344510/0/en/cingulate-inc-reports-second-quarter-2026-financial-results-and-provides-update-on-ctx-1301-cmc-progress-towards-nda-resubmission-and-commercial-readiness.html
See More Cingulate Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cingulate? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cingulate and other key companies, straight to your email.

About Cingulate

Cingulate (NASDAQ:CING) (NASDAQ:CING) is a clinical-stage biopharmaceutical company focused on developing treatments for attention-deficit/hyperactivity disorder (ADHD) and other central nervous system conditions. The company’s lead programs are based on its proprietary Precision Timed Release (PTR) drug-delivery platform, which is designed to provide controlled, timed releases of medication from a single oral dose.

Cingulate’s primary product candidate is CTx-1301, an extended-release formulation of dexmethylphenidate intended to provide all-day ADHD symptom control through multiple releases of the active ingredient. The company has also worked on additional investigational candidates, including CTx-1302, as it seeks to apply its delivery technology to other potential treatments.

Founded in 2012 and headquartered in Kansas City, Kansas, Cingulate has focused its clinical development activities primarily on the U.S. market. The company has no broadly marketed commercial product and continues to depend on clinical development and regulatory review for its candidates. Shane Schaffer, the company’s founder, has served as its chief executive officer.

View Cingulate Profile
Earnings Tools